SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: quidditch who wrote (632)3/24/2002 2:39:20 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3561
 
<<. Are the authors of the abstract simply saying "in the presence of VEGF" or something even more vague.>>

I think that you should read full JCI article.

Angio-2 mediate break down of the existing blood vessel close to tumor mass, while VEGF mediate new spurring from that vessels toward tumor. It is *vascular remodeling*. No new blood vessels from start, from inside tumors.

Miljenko